Trial Profile
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2023
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TOPIC
- Sponsors Sanofi
- 15 Oct 2021 Results of meta-analysis from three clinical studies: TOPIC, TALOS-AMI and TROPICAL-ACS published in the American Journal of Cardiovascular Drugs
- 26 May 2020 Results of pooled analysis from TEMSO, TOWER, TENERE, TOPIC and TERI-PRO assessing lymphocyte levels in teriflunomide-treated patients stratified by age, presented at the 6th Congress of the European Academy of Neurology
- 09 Jun 2019 Trial has been completed in UK according to European Clinical Trials Database record.